FOXP1 and colorectal carcinoma: By elucidating the mechanisms of FBXO44‐mediated FOXP1 degradation and its impact on CRC cell proliferation, we pave the way for future research to develop targeted therapies that can effectively inhibit CRC progression and improve patient outcomes.